|Videos|December 18, 2020

Safety and efficacy of KPI-121 0.25% for DED treatment

Author(s)David Hutton

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.


Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of dry eye disease in patients enrolled in four trials.

See more AAO coverage

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.


Latest CME